Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed

Summary

This study will test the safety and efficacy of TroVax in patients undergoing surgical resection of colorectal cancer with liver metastases. TroVax potentially works by encouraging the immune system to react against the 5T4 protein on the surface of bowel cancer cells. The immune system is then able to recognise 5T4 and kill cells that carry it. The hope is that if tumour cells started to grow again after the main tumour has been surgically removed, the immune system would be able to find and destroy them.

Timeline

Start

2004-06

Primary completion

—

Completion

2006-12

Drugs

Indications